Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer

por Scorilas, A, Kyriakopoulou, L, Katsaros, D, Diamandis, E P
Publicado 2001

Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects

por Shan, S J C, Scorilas, A, Katsaros, D, Diamandis, E P
Publicado 2007

TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival

por Mu, L, Katsaros, D, Lu, L, Preti, M, Durando, A, Arisio, R, Yu, H
Publicado 2008

Prostate-specific antigen in serum of women with breast cancer.

por Giai, M., Yu, H., Roagna, R., Ponzone, R., Katsaros, D., Levesque, M. A., Diamandis, E. P.
Publicado 1995

Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients.

por Zarghami, N., Giai, M., Yu, H., Roagna, R., Ponzone, R., Katsaros, D., Sismondi, P., Diamandis, E. P.
Publicado 1996

DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.

por Courjal, F., Cuny, M., Rodriguez, C., Louason, G., Speiser, P., Katsaros, D., Tanner, M. M., Zeillinger, R., Theillet, C.
Publicado 1996

Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer

por Kim, H, Scorilas, A, Katsaros, D, Yousef, G M, Massobrio, M, Fracchioli, S, Piccinno, R, Gordini, G, Diamandis, E P
Publicado 2001

Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker

por Hoffman, B R, Katsaros, D, Scorilas, A, Diamandis, P, Fracchioli, S, Rigault de la Longrais, I A, Colgan, T, Puopolo, M, Giardina, G, Massobrio, M, Diamandis, E P
Publicado 2002

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

por Bartlett, J. M., Langdon, S. P., Simpson, B. J., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W. N., Williams, A. R., Lessells, A. M., Macleod, K. G., Smyth, J. F., Miller, W. R.
Publicado 1996

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes

por Pecorelli, S., Ray-Coquard, I., Tredan, O., Colombo, N., Parma, G., Tisi, G., Katsaròs, D., Lhommé, C., Lissoni, A. A., Vermorken, J. B., du Bois, A., Poveda, A., Frigerio, L., Barbieri, P., Carminati, P., Brienza, S., Guastalla, J. P.
Publicado 2010

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

por Berruti, A, Bitossi, R, Gorzegno, G, Bottini, A, Generali, D, Milani, M, Katsaros, D, Rigault de la Longrais, I A, Bellino, R, Donadio, M, Ardine, M, Bertetto, O, Danese, S, Sarobba, M G, Farris, A, Lorusso, V, Dogliotti, L
Publicado 2005

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

por de Boer, S M, Wortman, B G, Bosse, T, Powell, M E, Singh, N, Hollema, H, Wilson, G, Chowdhury, M N, Mileshkin, L, Pyman, J, Katsaros, D, Carinelli, S, Fyles, A, McLachlin, C M, Haie-Meder, C, Duvillard, P, Nout, R A, Verhoeven-Adema, K W, Putter, H, Creutzberg, C L, Smit, V T H B M
Publicado 2018